Level C· Early human research exploring benefitsCohort StudyPubMed

Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance.

Ceperuelo-Mallafré V., Duran X., Pachón G., Roche K., Garrido-Sánchez L., Vilarrasa N.

Cohort Study on Type 2 Diabetes, published in J Clin Endocrinol Metab (2014) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Cohort Study
Journal
J Clin Endocrinol Metab (2014)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
24512489
DOI
10.1210/jc.2013-3350
Citations
83

Abstract (original English)

Context Glucose-dependent insulinotropic peptide (GIP) has a central role in glucose homeostasis through its amplification of insulin secretion; however, its physiological role in adipose tissue is unclear. Objective Our objective was to define the function of GIP in human adipose tissue in relation to obesity and insulin resistance. Design GIP receptor (GIPR) expression was analyzed in human sc adipose tissue (SAT) and visceral adipose (VAT) from lean and obese subjects in 3 independent cohorts. GIPR expression was associated with anthropometric and biochemical variables. GIP responsiveness on insulin sensitivity was analyzed in human adipocyte cell lines in normoxic and hypoxic environments as well as in adipose-derived stem cells obtained from lean and obese patients. Results GIPR expression was downregulated in SAT from obese patients and correlated negatively with body mass index, waist circumference, systolic blood pressure, and glucose and triglyceride levels. Furthermore, homeostasis model assessment of insulin resistance, glucose, and G protein-coupled receptor kinase 2 (GRK2) emerged as variables strongly associated with GIPR expression in SAT. Glucose uptake studies and insulin signaling in human adipocytes revealed GIP as an insulin-sensitizer incretin. Immunoprecipitation experiments suggested that GIP promotes the interaction of GRK2 with GIPR and decreases the as

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AdipocytesAdipose TissueAdultAgedBody Mass IndexCell LineDown-RegulationFemaleGastric Inhibitory PolypeptideHumans

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research